Gentherm Q1 Earnings Exceed Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy THRM?
Source: seekingalpha
- Earnings Beat: Gentherm reported a Q1 Non-GAAP EPS of $0.84, surpassing expectations by $0.33, indicating a significant improvement in profitability and enhanced competitive positioning in the market.
- Revenue Growth: The company achieved revenue of $393.71 million in Q1, an 11.3% year-over-year increase, exceeding market expectations by $31.48 million, demonstrating strong performance in product sales and market demand.
- Cash Flow Improvement: Although cash flow from operations was negative at $(5.0) million, this represents an improvement from $(13.3) million in the prior year, highlighting progress in cash management and operational efficiency.
- Stable Future Guidance: Gentherm's guidance for full-year 2026 remains unchanged, projecting product revenues between $1.5 billion and $1.6 billion and adjusted EBITDA of $175 million to $195 million, reflecting confidence in future growth and a stable business foundation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy THRM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on THRM
Wall Street analysts forecast THRM stock price to rise
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 28.890
Low
42.00
Averages
43.33
High
44.00
Current: 28.890
Low
42.00
Averages
43.33
High
44.00
About THRM
Gentherm Incorporated is a provider of thermal management and pneumatic comfort technologies. The Company operates in two segments: Automotive and Medical. The Automotive reporting segment comprises global automotive businesses, including the design, development, manufacturing and sales of its automotive climate and comfort solutions (including Climate Control Seats, Climate Control Interiors, Lumbar and Massage Comfort Solutions and Climate and Comfort Electronics), Valve Systems and other automotive products. The Medical reporting segment comprises the patient temperature management business in the medical industry. Patient temperature management includes temperature management systems across multiple product categories addressing the needs of hyper-hypothermia therapy in intensive care, normothermia in surgical procedures and additional warming/cooling therapies utilized in acute and chronic care departments and non-hospital facilities.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GENTHERM Q1 EPS Revised to USD 0.14 (Amount Correction)
- Correction Notice: The article includes a correction regarding the amount reported in the previous version.
- Financial Update: The corrected figure for Q1 EPS is now stated as $0.14.
See More
Gentherm Q1 Earnings Exceed Expectations
- Earnings Beat: Gentherm reported a Q1 Non-GAAP EPS of $0.84, surpassing expectations by $0.33, indicating a significant improvement in profitability and enhanced competitive positioning in the market.
- Revenue Growth: The company achieved revenue of $393.71 million in Q1, an 11.3% year-over-year increase, exceeding market expectations by $31.48 million, demonstrating strong performance in product sales and market demand.
- Cash Flow Improvement: Although cash flow from operations was negative at $(5.0) million, this represents an improvement from $(13.3) million in the prior year, highlighting progress in cash management and operational efficiency.
- Stable Future Guidance: Gentherm's guidance for full-year 2026 remains unchanged, projecting product revenues between $1.5 billion and $1.6 billion and adjusted EBITDA of $175 million to $195 million, reflecting confidence in future growth and a stable business foundation.
See More
Modine Appoints Art Laszlo as President of New Data Centers Segment
- Leadership Change: Modine has announced the promotion of Art Laszlo to President of the newly created Data Centers segment, responsible for driving growth and profitability, indicating a strategic shift in the company's focus towards the data center market.
- Market Opportunity: The establishment of the new Data Centers segment reflects Modine's recognition of the increasing demand for cooling solutions from global data center operators, which is expected to further solidify its market leadership.
- Business Structure Adjustment: The Data Centers segment was previously part of the Climate Solutions segment, and with Laszlo's appointment, Modine will report the performance of these two segments in the first quarter of fiscal 2027, demonstrating the company's emphasis on business segmentation.
- Leadership Experience: Since joining Modine in 2022, Laszlo has progressively advanced to senior leadership roles, and his extensive experience at IDEX and other renowned companies will provide strategic guidance to the new segment.
See More
Gentherm Partners with KNB to Launch Innovative Medical Device
- Strategic Partnership Announced: Gentherm has partnered with KNB Communications, which will serve as the official PR agency for Gentherm's medical division, leveraging its expertise to support the launch of the ThermAffyx™ Patient Safety System aimed at enhancing patient safety during surgeries.
- Innovative Product Introduction: The ThermAffyx™ Patient Safety System is the first medical device designed to integrate patient warming and securement, addressing dual challenges faced during surgeries, which is expected to significantly improve patient experience and safety in surgical settings.
- FDA Application Progress: Gentherm submitted a 510(k) Class II premarket notification to the FDA for the ThermAffyx™ earlier this year, with clearance anticipated in May, paving the way for market entry and enhancing competitive positioning.
- Significant Market Potential: Gentherm recorded approximately $1.5 billion in annual sales in 2024 and secured $2.4 billion in new automotive business awards, indicating strong growth potential and strategic importance in expanding its footprint in the medical device market, particularly in innovations related to patient safety.
See More
Gentherm Partners with KNB to Launch Innovative Medical Device
- Strategic Partnership Announced: Gentherm has partnered with KNB Communications, which will serve as the official PR agency for Gentherm's medical division, leveraging its expertise to support the launch of the ThermAffyx™ Patient Safety System aimed at enhancing patient safety during surgeries.
- Innovative Medical Device: The ThermAffyx™ Patient Safety System is the first medical device designed to integrate patient warming and securement challenges into a single solution, addressing a critical clinical need and expected to significantly improve patient safety during surgical procedures.
- FDA Application Progress: Gentherm submitted a 510(k) Class II premarket notification for ThermAffyx™ to the FDA earlier this year, with clearance anticipated in May, paving the way for the product's market introduction.
- Significant Market Potential: Gentherm recorded approximately $1.5 billion in annual sales in 2024 and secured $2.4 billion in new automotive business awards, highlighting its strong potential and growth prospects in the medical device market.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives that could influence investor decisions.
- Market Dynamics: As analysts revise their outlook on THRM stock, investors may consider buying or selling, potentially impacting its market performance and liquidity, thereby increasing market uncertainty.
- Impact of Rating Changes: Changes in analyst ratings often have a direct effect on stock prices, prompting investors to closely monitor these shifts to timely adjust their investment strategies and optimize their portfolios.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, and investors should reference these ratings for a more comprehensive market view.
See More
GENTHERM Q1 EPS Revised to USD 0.14 (Amount Correction)
- Correction Notice: The article includes a correction regarding the amount reported in the previous version.
- Financial Update: The corrected figure for Q1 EPS is now stated as $0.14.
See More
Gentherm Q1 Earnings Exceed Expectations
- Earnings Beat: Gentherm reported a Q1 Non-GAAP EPS of $0.84, surpassing expectations by $0.33, indicating a significant improvement in profitability and enhanced competitive positioning in the market.
- Revenue Growth: The company achieved revenue of $393.71 million in Q1, an 11.3% year-over-year increase, exceeding market expectations by $31.48 million, demonstrating strong performance in product sales and market demand.
- Cash Flow Improvement: Although cash flow from operations was negative at $(5.0) million, this represents an improvement from $(13.3) million in the prior year, highlighting progress in cash management and operational efficiency.
- Stable Future Guidance: Gentherm's guidance for full-year 2026 remains unchanged, projecting product revenues between $1.5 billion and $1.6 billion and adjusted EBITDA of $175 million to $195 million, reflecting confidence in future growth and a stable business foundation.
See More
Modine Appoints Art Laszlo as President of New Data Centers Segment
- Leadership Change: Modine has announced the promotion of Art Laszlo to President of the newly created Data Centers segment, responsible for driving growth and profitability, indicating a strategic shift in the company's focus towards the data center market.
- Market Opportunity: The establishment of the new Data Centers segment reflects Modine's recognition of the increasing demand for cooling solutions from global data center operators, which is expected to further solidify its market leadership.
- Business Structure Adjustment: The Data Centers segment was previously part of the Climate Solutions segment, and with Laszlo's appointment, Modine will report the performance of these two segments in the first quarter of fiscal 2027, demonstrating the company's emphasis on business segmentation.
- Leadership Experience: Since joining Modine in 2022, Laszlo has progressively advanced to senior leadership roles, and his extensive experience at IDEX and other renowned companies will provide strategic guidance to the new segment.
See More
Gentherm Partners with KNB to Launch Innovative Medical Device
- Strategic Partnership Announced: Gentherm has partnered with KNB Communications, which will serve as the official PR agency for Gentherm's medical division, leveraging its expertise to support the launch of the ThermAffyx™ Patient Safety System aimed at enhancing patient safety during surgeries.
- Innovative Product Introduction: The ThermAffyx™ Patient Safety System is the first medical device designed to integrate patient warming and securement, addressing dual challenges faced during surgeries, which is expected to significantly improve patient experience and safety in surgical settings.
- FDA Application Progress: Gentherm submitted a 510(k) Class II premarket notification to the FDA for the ThermAffyx™ earlier this year, with clearance anticipated in May, paving the way for market entry and enhancing competitive positioning.
- Significant Market Potential: Gentherm recorded approximately $1.5 billion in annual sales in 2024 and secured $2.4 billion in new automotive business awards, indicating strong growth potential and strategic importance in expanding its footprint in the medical device market, particularly in innovations related to patient safety.
See More
Gentherm Partners with KNB to Launch Innovative Medical Device
- Strategic Partnership Announced: Gentherm has partnered with KNB Communications, which will serve as the official PR agency for Gentherm's medical division, leveraging its expertise to support the launch of the ThermAffyx™ Patient Safety System aimed at enhancing patient safety during surgeries.
- Innovative Medical Device: The ThermAffyx™ Patient Safety System is the first medical device designed to integrate patient warming and securement challenges into a single solution, addressing a critical clinical need and expected to significantly improve patient safety during surgical procedures.
- FDA Application Progress: Gentherm submitted a 510(k) Class II premarket notification for ThermAffyx™ to the FDA earlier this year, with clearance anticipated in May, paving the way for the product's market introduction.
- Significant Market Potential: Gentherm recorded approximately $1.5 billion in annual sales in 2024 and secured $2.4 billion in new automotive business awards, highlighting its strong potential and growth prospects in the medical device market.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives that could influence investor decisions.
- Market Dynamics: As analysts revise their outlook on THRM stock, investors may consider buying or selling, potentially impacting its market performance and liquidity, thereby increasing market uncertainty.
- Impact of Rating Changes: Changes in analyst ratings often have a direct effect on stock prices, prompting investors to closely monitor these shifts to timely adjust their investment strategies and optimize their portfolios.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, and investors should reference these ratings for a more comprehensive market view.
See More
